Trial Details

Not Recruiting
Basic Information
Clinical ID c3077
Identifier ISRCTN79241600
Trial Title A double-blind, placebo-controlled, single and multiple ascending dose phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of CCX507-B in healthy male and female subjects
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Inflammatory Bowel Diseases (IBD) such as ulcerative colitis (UC) or Crohn?s disease (CD) Digestive System
Interventions CCX507-B (30, 60 and 90 mg CCX507-B single dose and multiple doses for 7 days) or placebo. Period 1 involves subjects being randomized to CCX507-B or placebo and being dosed a single time. Period 2 involved subjects being randomized to CCX507-B or placebo and being dosed over a period of 7 days. After the conclusion of Period 2, subjects are followed for 3 weeks.
Participant Information
Sponsor ChemoCentryx, Inc. (USA)
City -
Country/Region Netherlands
Enrollment Criteria
Sex Requirement ALL
Age Requirement -
Study Design
Study Type Interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -